Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 397,364
  • Shares Outstanding, K 24,200
  • Annual Sales, $ 2,430 K
  • Annual Income, $ -27,120 K
  • 60-Month Beta 0.80
  • Price/Sales 166.55
  • Price/Cash Flow N/A
  • Price/Book 2.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.54
  • Number of Estimates 4
  • High Estimate -0.51
  • Low Estimate -0.55
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -42.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.33 +14.58%
on 09/27/19
18.12 -9.38%
on 10/15/19
-0.75 (-4.37%)
since 09/18/19
3-Month
14.33 +14.58%
on 09/27/19
24.67 -33.43%
on 07/24/19
-7.58 (-31.58%)
since 07/18/19
52-Week
14.33 +14.58%
on 09/27/19
36.95 -55.56%
on 12/06/18
-6.98 (-29.83%)
since 10/18/18

Most Recent Stories

More News
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)
What Makes Crinetics Pharmaceuticals (CRNX) a Strong Sell?

Crinetics Pharmaceuticals (CRNX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

FGEN : 38.80 (-4.22%)
CRNX : 16.42 (-1.74%)
Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for...

CRNX : 16.42 (-1.74%)
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)
Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)
Market Trends Toward New Normal in GrafTech International, Avinger, OraSure Technologies, Adamis Pharmaceuticals, Crinetics Pharmaceuticals, and Wayside Technology Group -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd....

EAF : 11.42 (+0.88%)
AVGR : 1.11 (+21.98%)
OSUR : 8.48 (unch)
ADMP : 0.54 (-3.90%)
CRNX : 16.42 (-1.74%)
WSTG : 14.49 (+0.63%)
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and...

CRNX : 16.42 (-1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRNX with:

Business Summary

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly,...

See More

Key Turning Points

2nd Resistance Point 17.43
1st Resistance Point 16.92
Last Price 16.42
1st Support Level 15.88
2nd Support Level 15.35

See More

52-Week High 36.95
Fibonacci 61.8% 28.31
Fibonacci 50% 25.64
Fibonacci 38.2% 22.97
Last Price 16.42
52-Week Low 14.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar